MedPath

NEUROLIEF LTD

🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:5

Trial Phases

1 Phases

Not Applicable:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Not Applicable
7 (100.0%)

Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine

Not Applicable
Withdrawn
Conditions
Migraine
First Posted Date
2023-04-07
Last Posted Date
2024-12-02
Lead Sponsor
Neurolief Ltd.
Target Recruit Count
57
Registration Number
NCT05804396

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Not Applicable
Completed
Conditions
MDD
First Posted Date
2020-02-21
Last Posted Date
2024-08-16
Lead Sponsor
Neurolief Ltd.
Target Recruit Count
126
Registration Number
NCT04279522
Locations
🇺🇸

Kadima Neuropsychiatry Institute, La Jolla, California, United States

🇺🇸

UCLA Semel Institute for Neuroscience and Behaviour, Los Angeles, California, United States

🇺🇸

San Marcus Research Clinic, Miami Lakes, Florida, United States

and more 10 locations

The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Not Applicable
Completed
Conditions
Acute Migraine
First Posted Date
2018-08-15
Last Posted Date
2022-09-22
Lead Sponsor
Neurolief Ltd.
Target Recruit Count
187
Registration Number
NCT03631550
Locations
🇺🇸

Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States

🇺🇸

Hartford HealthCare Headache Center, Hartford, Connecticut, United States

🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

and more 7 locations

Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

Not Applicable
Completed
Conditions
Migraine
First Posted Date
2018-01-12
Last Posted Date
2019-03-13
Lead Sponsor
Neurolief Ltd.
Target Recruit Count
55
Registration Number
NCT03398668
Locations
🇮🇱

Laniado Medcial Center, Netanya, Israel

A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.

Not Applicable
Terminated
Conditions
Migraine
First Posted Date
2017-06-14
Last Posted Date
2018-03-29
Lead Sponsor
Neurolief Ltd.
Target Recruit Count
8
Registration Number
NCT03185559
Locations
🇮🇱

Meir General Hospital, Kfar Saba, Israel

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.